Anthony E. Altig has served as a Director since January 2009. He is the Chief Financial Officer of Biotix Holdings, a manufacturer and distributor of microbiology and molecular biology consumables. From December 2004 to June 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corporation (subsequently Verenium Corporation), a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company, from 2002 to 2004. From 2000 to 2001, Mr. Altig served as the Chief Financial Officer of NBC Internet, Inc., an internet portal company, which was acquired by General Electric. Mr. Altig's additional experience includes his role as the Chief Accounting Officer at US Web Corporation, as well as his experience serving biotechnology and other technology companies during his tenure at both PricewaterhouseCoopers LLP and KPMG LLP. Mr. Altig serves as a Director and Audit Committee member for Optimer Pharmaceuticals, Inc. and is also a Director and Audit Committee Member for Ventrus Biosciences. Mr. Altig received a BBA degree from the University of Hawaii.
Seph Jensen, Chief Executive Officer of TearLab Corporation, graduated from Flagler College in 1994 with a double major in business administration and marketing, and a minor in advertising. Seph Jensen, Chief Executive Office of TearLab Corporation, graduated from Flagler College in 1994 with a double major in business administration and marketing, and a minor in advsrtising. Seph started his career at ADP as the top sales person in the Orlando region. He then moved to Jacksonville to take a position with Warner Lambert. In 1996, Seph joined Alcon Laboratories where he embarked on a 17-year tenure serving in the pharmaceutical and medical device sectors. His roles included various commercial positions with focus in sales and marketing. His time with Alcon was split between local markets within the US and Japan along with Alcon headquarters in Fort Worth, TX. In 2012, Seph was promoted to the Head of Surgical Marketing, and was responsible for over $1.4 Billion in revenue. In October 2013, Seph joined TearLab as the President and Chief Operating Officer and, as a seasoned leader with in-depth knowledge in the eye care category and a strong track record of delivering operational excellence and profitable growth, is poised to continue the company’s growth and success.
Paul M. Karpecki, O.D., FAAO
Dr. Paul Karpecki is currently the Director of Ocular Disease Research and also works in Corneal Services at Koffler Vision Group in Lexington KY since March of 2009. In 2007 he accepted a position with the Cincinnati Eye Institute in Corneal Services after five years as Director of Research for the Moyes Eye Clinic in Kansas City. Dr. Karpecki serves on or chairs numerous optometric association committees including Chair of the Refractive Surgery Advisory Committee to the AOA and on the AOA Meetings Executive Committee. He has lectured in more than 300 symposia covering four continents and was the first Optometrist to be invited to both the Delphi International Society at Wilmer-John's Hopkins, which includes the top 25 dry eye experts in the world, and the National Eye Institute's Dry Eye Committee. This was a task force established by the U.S. Department of Health and Human Services to better understand and treat dry eye disease in women. A noted educator and author, Dr. Karpecki lectures on new technology, surgical advancements and therapeutics with an emphasis on cornea and external disease. He presently serves on eight professional journal Editorial Boards. Dr. Karpecki received his Doctorate of Optometry from Indiana University and completed a Fellowship in Cornea and Refractive Surgery at Hunkeler Eye Centers in affiliation with the Pennsylvania College of Optometry in 1994.
Richard L. Lindstrom, M.D.
Dr. Richard L. Lindstrom, founder and attending surgeon of Minnesota Eye Consultants and Adjunct Professor Emeritus at the University Of Minnesota Department of Ophthalmology, is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery. He has been at the forefront of ophthalmology's revolutionary changes throughout his career, as a recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon.After graduating Magna Cum Laude from the College of Liberal Arts at the University of Minnesota, Dr. Lindstrom completed his doctorate degree in medicine in 1972. He conducted research, residency and fellowship training in cornea at the University of Minnesota and affiliated hospitals and extended his anterior segment surgery fellowship training at Mary Shiels Hospital in Dallas and was a Heed Fellow in Glaucoma at University Hospital in Salt Lake City. In 1980, Dr. Lindstrom returned to the University of Minnesota, where he spent ten years on the faculty of the Department of Ophthalmology, the last two as a full professor and the Harold G. Scheie Research Chair. He continues as Adjunct Professor Emeritus, Chairman of the Vision Foundation, and Associate Director of the Minnesota Lions Eye Bank at the University of Minnesota. He entered private practice in 1989, and has led the growth and expansion of Minnesota Eye Consultants serving as managing partner for 15 years.He is medical director of Sightpath Medical, which includes MSS and Laser Vision. He is also medical director of Refractec.He is Chief Medical Editor of the USA and International editions of Ocular Surgery News, which reaches 82,000 Ophthalmologists worldwide.Dr. Lindstrom is past President of the American Society of Cataract and Refractive Surgeons. He serves on the Executive Committee and is the Chair of the ASCRS Foundation. He is also past President of the International Society of Refractive Surgery, the International Intraocular Implant Club, and the International Refractive Surgery Club. He is the Global Education Liaison of the International Society of Refractive Surgery of the American Academy of Ophthalmology. He is Chairman and CEO of Lindstrom Restoration, a three-generation family business. He has endowed funds supporting the University of Minnesota, Department of Ophthalmology, the Eye Bank Association of America, and the University of Minnesota Tennis Team.Dr Lindstrom holds over 35 patents in ophthalmology and has developed a number of solutions, intraocular lenses and instruments that are used in clinical practices globally. He serves on the Board of Directors of AcuFocus, Inc, TLC Vision, TearLab Corporation, Refractec, the Minnesota Medical Foundation, and Inner City Tennis.A frequent lecturer throughout the world on cornea, cataract and refractive surgery, he has presented over 40 named lectures and keynote speeches before professional societies in the U.S. and abroad, most recently giving the Blumenthal Memorial lecture in Jerusalem, Israel, the Benedetto Strampelli Medal Lecture in Rome, Italy, and the Albrecht von Garefe-Vorlesung Innovator's Lecture in Nuremberg, Germany, IIIC Medal Lecture in Berlin, Germany.Dr. Lindstrom serves on a number of journal editorial boards, including JCRS, JRS, and Ophthalmic Surgery. He is the Honorary Editor-in-Chief of the U.S./Chinese Journal of Ophthalmology. He has co-edited seven books, published over 350 peer reviewed journal articles and 60 book chapters. His professional affiliations are extensive, including Liaison of the International Society of Refractive Surgery of the American Academy of Ophthalmology.
Prior to TearLab, Mr. Vamvakas co-founded TLCVision (NASDAQ/TLCV, TSX/TLC) in 1993 where he served as President and CEO until 2003.Mr. Vamvakas as CEO, built TLC into the largest eye care service provider organization in North America with revenues of more than $300,000,000 as TLC opened or acquired more than 100 laser eye clinics, over 200 mobile laser sites, more than 250 mobile cataract locations, several ambulatory surgery centers, and through its subsidiary Vision Source Inc. developed the largest independent Optometric Franchise with more than 2,000 locations.TLC's stock, listed on the TSX and NASDAQ since 1996, appreciated to well over $1 billion during his tenure.Mr. Vamvakas is also the Chairman of Greybrook Capital, a private equity investment firm based out of Toronto that is focused on acquiring and operating companies in Financial Services, Technology and Healthcare. Mr. Vamvakas is also Chairman of Brandimensions Inc and serves on the Board of Jameson Bank.Mr. Vamvakas has received many management awards from industry and his peers.
Mr. Vamvakas was named to 'Canada's Top Forty under Forty' in 1996 - an award that recognizes the top 40 Canadians under the age of 40
In 2005 he was also voted "best of the best" by his peers.
In 2000, Mr. Vamvakas was recognized by Profit Magazine for managing Canada's fastest growing company (TLC) with over 25,000% growth over 5 years.
In 1999, Mr. Vamvakas received the Presidential Medal of Honor from the Illinois College of Optometry.
In 1999 he was named Ernst & Young's Canadian Entrepreneur of the Year for Innovative Partnering and Entrepreneur of the Year for Ontario in the Emerging Category.